AVADEL PHARMACEUTICALS PLC(AVDL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
AVDL Stock Analysis & AI Quality Score
AI stock analysis and institutional research for AVADEL PHARMACEUTICALS PLC (AVDL), a Healthcare sector company. AVDL is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q3 2025), AVADEL PHARMACEUTICALS PLC reports quarterly revenue of $77.5M, net income of $20.0K, an operating margin of 2.5%. Top institutional holders of AVDL by reported 13-F value include BlackRock,, VANGUARD GROUP, GENDELL JEFFREY L, based on the most recent SEC filings. AVDL trades on the Nasdaq exchange and files with the SEC under CIK 1012477. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVDL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AVADEL PHARMACEUTICALS PLC directly from SEC EDGAR.
Revenue
Q3 2025
$77.5M
Net Income
Q3 2025
$20.0K
Free Cash Flow
Q3 2025
$22.2M
Operating Margin
Q3 2025
2.5%
ROIC
Q3 2025
2.0%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+504.8% YoYNet Income
+69.5% YoYOperating Income
+69.2% YoYEPS (Diluted)
+74.5% YoYTotal Assets
-0.3% YoYTotal Debt
Op. Cash Flow
+63.5% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | $169.1M +504.8% | $28.0M | $0.00 | $0.00 -100.0% | $59.2M -42.7% | $103.3M |
| Net Income | $-48.8M +69.5% | $-160.3M -16.6% | $-137.5M -77.8% | $-77.3M -132.7% | $-33.2M +65.1% | $-95.3M |
| Operating Income | $-42.4M +69.2% | $-137.8M -39.9% | $-98.6M -15.2% | $-85.5M -254.8% | $-24.1M +77.0% | $-104.9M |
| EPS (Diluted) | $-0.51 +74.5% | $-2.00 +12.7% | $-2.29 -73.5% | $-1.32 -48.3% | $-0.89 +65.1% | $-2.55 |
| Total Assets | $164.2M -0.3% | $164.7M +24.0% | $132.8M -46.3% | $247.3M +63.3% | $151.4M -20.4% | $190.3M |
| Total Debt | — | — | $129.3M -9.2% | $142.4M +17.0% | $121.7M +5.0% | $115.9M |
| Operating Cash Flow | $-46.9M +63.5% | $-128.5M -82.8% | $-70.3M +9.1% | $-77.3M -101.7% | $-38.3M +53.7% | $-82.7M |
Get alerted when AVDL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for AVADEL PHARMACEUTICALS PLC including:
Top Institutional Holders of AVDL
BlackRock, Inc.
$151.7M7,041,102 shVANGUARD GROUP INC
$126.4M5,864,781 shGENDELL JEFFREY L
$102.8M4,769,357 shWeiss Asset Management LP
$97.3M4,515,114 shTIG Advisors, LLC
$83.2M3,859,122 shTUDOR INVESTMENT CORP ET AL
$64.3M2,983,541 shFIL Ltd
$60.8M2,822,777 shVivo Capital, LLC
$57.8M2,684,109 shSTATE STREET CORP
$49.1M2,278,301 shGEODE CAPITAL MANAGEMENT, LLC
$46.5M2,156,356 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $151.7M | 7,041,102 |
| VANGUARD GROUP INC | $126.4M | 5,864,781 |
| GENDELL JEFFREY L | $102.8M | 4,769,357 |
| Weiss Asset Management LP | $97.3M | 4,515,114 |
| TIG Advisors, LLC | $83.2M | 3,859,122 |
| TUDOR INVESTMENT CORP ET AL | $64.3M | 2,983,541 |
| FIL Ltd | $60.8M | 2,822,777 |
| Vivo Capital, LLC | $57.8M | 2,684,109 |
| STATE STREET CORP | $49.1M | 2,278,301 |
| GEODE CAPITAL MANAGEMENT, LLC | $46.5M | 2,156,356 |
More Healthcare Companies
View all Healthcare →Put AVDL on your watchlist
Track score changes the day AVADEL PHARMACEUTICALS PLC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AVDL a good stock to buy?
13F Pro's AI-powered analysis of AVADEL PHARMACEUTICALS PLC (AVDL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AVDL are available on the AVDL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own AVDL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AVDL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AVADEL PHARMACEUTICALS PLC's investment landscape.